

Insight Molecular Diagnostics Inc. (IMDX)

Nasdaq; healthcare; SIC 2835, In Vitro & In Vivo Diagnostic Substances; CIK 0001642380

[illegible]

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 26, 2026

We are a pioneering diagnostics technology company. Our mission is to expand access to novel molecular diagnostic testing, most immediately in the transplanted organ rejection testing category. We are developing molecular diagnostic test kits designed to empower our customers to run their own tests in-house to participate in the patient-care value chain, which is counter-positioned with the send-out-testing central laboratory model. Our decentralized approach also puts testing in the hands of researchers to enable more

studies, which we believe can improve standards of care while also creating demand for more testing.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 59.4						
Gross profitability		8.9%	32.2%	77.4	372	2025-12-31
Return on invested capital		not computable	9.3%			required facts have no common fiscal period end
Accruals ratio		(92.2%)	(6.6%)	4.4	811	2025-12-31
Gross margin stability, five years		23.5 pts	2.8 pts	96.3	243	2025-12-31
Solvency, sleeve percentile 87.5						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(63.82)	(0.31)	90.7	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000 interest expense must exceed \$100,000
Interest coverage		not computable	(4.51x)			
Current ratio		1.27x	2.96x	84.4	839	2025-12-31
Growth and financing, sleeve percentile 53.1						
Revenue growth, three-year compound		61.8%	10.0%	9.7	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		(36.4%)	2.1%	95.2	704	2025-12-31
Net share issuance, one year		12.5%	2.5%	54.3	634	2026-03-19


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 5,730,000 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
325	Lexaria Bioscience Corp. (LEXX)	87.6	E	dilution, short runway, distress
326	Intelligent BIO Solutions Inc. (INBS)	87.8	E	dilution, short runway
327	Bristol Myers Squibb Co. (BMY)	88.2	E	
328	Bristol Myers Squibb Co. (CELG-RI)	88.2	E	
329	Maravai Lifesciences Holdings, Inc. (MRVI)	88.6	E	late filer
330	Insight Molecular Diagnostics Inc. (IMDX) <	88.9	E	fortress
331	Nuwellis, Inc. (NUWE)	89.2	E	balance sheet dilution, short runway, fortress
332	Aclaris Therapeutics, Inc. (ACRS)	89.5	E	balance sheet short runway, fortress
333	Brookdale Senior Living Inc. (BKD)	89.7	E	balance sheet
334	Lifeward Ltd. (LFWD)	90.0	E	dilution, late filer
335	Canopy Growth Corp. (CGC)	90.3	E	dilution, fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	18.1%	8.0%	57
Distance from 52-week high	(61.3%)	(31.4%)	16
EBIT to enterprise value	(55.9%)	(1.5%)	12
Free cash flow yield	(23.6%)	(1.0%)	21
Book value to price	(0.20)	0.28	6
Sales to price	0.04	0.31	13
Composite equity issuance, five years	199.6%	20.3%	90
Relative strength against the sector, log excess return	(0.05)	(0.14)	57

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass

Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$17.8M
Operating cash flow, four quarters	-\$27.1M
Months of runway	7.9
Days since last periodic filing	60 (10-Q received Aug 10, 2026)
Median daily dollar volume, 63 sessions	\$756,319

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$2.3M	2025-12-31	2026-03-26	10-K	0001642380-26-000004
2	assets	us-gaap:Assets	\$25.8M	2025-12-31	2026-03-26	10-K	0001642380-26-000004
3	net income	us-gaap:NetIncomeLoss	-\$50.2M	2025-12-31	2026-03-26	10-K	0001642380-26-000004
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$22.2M	2025-12-31	2026-03-26	10-K	0001642380-26-000004
5	assets	us-gaap:Assets	\$35.1M	2024-12-31	2026-03-26	10-K	0001642380-26-000004
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$4.1M	2025-12-31	2026-03-26	10-K	0001642380-26-000004
7	gross profit	us-gaap:GrossProfit	\$740,000	2024-12-31	2026-03-26	10-K	0001642380-26-000004
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.9M	2024-12-31	2026-03-26	10-K	0001642380-26-000004
9	gross profit	us-gaap:GrossProfit	\$413,000	2023-12-31	2025-03-24	10-K	0000950170-25-043852
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.5M	2023-12-31	2025-03-24	10-K	0000950170-25-043852
11	gross profit	us-gaap:GrossProfit	-\$18,000	2022-12-31	2024-04-16	10-K	0001493152-24-014720
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$958,000	2022-12-31	2024-04-16	10-K	0001493152-24-014720
13	gross profit	us-gaap:GrossProfit	\$1.4M	2021-12-31	2023-04-12	10-K	0001493152-23-012005
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$2.2M	2021-12-31	2023-04-12	10-K	0001493152-23-012005
15	current assets	us-gaap:AssetsCurrent	\$15.3M	2025-12-31	2026-03-26	10-K	0001642380-26-000004
16	current liabilities	us-gaap:LiabilitiesCurrent	\$12.1M	2025-12-31	2026-03-26	10-K	0001642380-26-000004
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$400.8M	2025-12-31	2026-03-26	10-K	0001642380-26-000004
18	operating income	us-gaap:OperatingIncomeLoss	-\$51.1M	2025-12-31	2026-03-26	10-K	0001642380-26-000004
19	book equity	us-gaap:StockholdersEquity	-\$31.5M	2025-12-31	2026-03-26	10-K	0001642380-26-000004
20	liabilities	us-gaap:Liabilities	\$57.2M	2025-12-31	2026-03-26	10-K	0001642380-26-000004
21	total debt	us-gaap:LongTermDebt	\$1.9M	2017-12-31	2018-04-02	10-K	0001140361-18-016477
22	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$7.6M	2017-12-31	2019-04-01	10-K	0001493152-19-004549
23	operating income	us-gaap:OperatingIncomeLoss	-\$18.8M	2017-12-31	2019-04-01	10-K	0001493152-19-004549
24	depreciation amortization	us-gaap:Depreciation	\$338,000	2017-12-31	2019-04-01	10-K	0001493152-19-004549
25	operating income	us-gaap:OperatingIncomeLoss	-\$11.1M	2016-12-31	2018-04-02	10-K	0001140361-18-016477
26	interest expense	us-gaap:InterestExpense	\$0	2016-12-31	2017-02-27	10-K	0001140361-17-009369
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$3.2M	2025-12-31	2026-03-26	10-K	0001642380-26-000004
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$20.7M	2024-12-31	2026-03-26	10-K	0001642380-26-000004
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$516,000	2024-12-31	2026-03-26	10-K	0001642380-26-000004
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$23.3M	2023-12-31	2025-03-24	10-K	0000950170-25-043852
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$281,000	2023-12-31	2025-03-24	10-K	0000950170-25-043852
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$45.6M	2022-12-31	2024-04-16	10-K	0001493152-24-014720
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$4.3M	2022-12-31	2024-04-16	10-K	0001493152-24-014720
34	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$1.6M	2024-12-31	2026-03-26	10-K	0001642380-26-000004
35	operating income	us-gaap:OperatingIncomeLoss	-\$61.0M	2024-12-31	2026-03-26	10-K	0001642380-26-000004
36	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$50.7M	2025-12-31	2026-03-26	10-K	0000950170-25-043852
37	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2024-12-31	2026-03-26	10-K	0001642380-26-000004
38	current assets	us-gaap:AssetsCurrent	\$11.8M	2024-12-31	2026-03-26	10-K	0001642380-26-000004
39	current liabilities	us-gaap:LiabilitiesCurrent	\$7.3M	2024-12-31	2026-03-26	10-K	0001642380-26-000004
40	current assets	us-gaap:AssetsCurrent	\$10.7M	2023-12-31	2025-03-24	10-K	0000950170-25-043852
41	current liabilities	us-gaap:LiabilitiesCurrent	\$7.2M	2023-12-31	2025-03-24	10-K	0000950170-25-043852
42	assets	us-gaap:Assets	\$74.9M	2023-12-31	2025-03-24	10-K	0000950170-25-043852
43	assets	us-gaap:Assets	\$100.1M	2022-12-31	2024-04-16	10-K	0001493152-24-014720
44	shares outstanding	dei:EntityCommonStockSharesOutstanding	32,167,978	2026-03-19	2026-03-26	10-K	0001642380-26-000004
45	shares outstanding	dei:EntityCommonStockSharesOutstanding	28,599,285	2025-03-17	2025-03-24	10-K	0000950170-25-043852